Abiopharma

MARZETTI CO (MZTI) Reports the reporting period Financial Results MARZETTI CO (MZTI) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 927054
• Net Income: 48290
• EPS: 0.91
• Cash and equivalents: $18
  • planned for introduction for both our legacy brands and licensing program. In the Foodservice segment, we expect sales to be supported by select quick-service restaurant customers in our mix of national chain restaurant accounts. Note that external factors, including U.S. economic performance and consumer behavior, may impact the topline growth for both segments in the coming year. We also continue to monitor the impact of the Cyclospora outbreak on product demand and sales. With respect to our input costs, in aggregate we anticipate a moderate level of inflation in fiscal 2027